- Home
- MARPS vs RDHL Comparison
MARPS vs RDHL Comparison
Compare MARPS & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | RDHL |
|---|---|---|
| Founded | 1956 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 3.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MARPS | RDHL |
|---|---|---|
| Price | $4.30 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.8K | ★ 75.2K |
| Earning Date | 02-13-2026 | 09-05-2025 |
| Dividend Yield | ★ 8.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $965,040.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $3.34 | $1.01 |
| 52 Week High | $7.90 | $7.43 |
Technical Indicators
Market Signals| Indicator | MARPS | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 49.52 |
| Support Level | $4.09 | $1.14 |
| Resistance Level | $4.43 | $1.26 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 21.39 | 71.05 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.